Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT02310178
Recruiting Not applicable

Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery

NCT02310178 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Montpellier
Phase
Not applicable
Started
2012-05-21
Last updated
2026-06-22

Condition(s) studied

Obesity, MorbidBariatric Surgery Candidate

Investigational drug(s) / intervention(s)

Bariatric surgery

Bariatric surgery: all of the current bariatric surgeries are allowed in this prospective cohort study

Study summary

The aim of this cohort is to evaluate the follow-up of morbidly obese patients treated by several types of bariatric procedures. In addition, this study could lead to the development of clinical trials on assessment of the bariatric surgery impact.

Eligibility

Sex
ALL
Min age
15 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Only be considered in patients operated and followed at CHU Montpellier with bariatric surgery * Patients treated by bariatric surgery on CHU Montpellier * Agreed to participate to the study by signing an informed consent * Eligible to health insurance Exclusion Criteria: * Unable to follow the patient in the long term (foreign patients, surgical use ...) * Inability to follow in the long run

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHRU - Hôpital Saint Eloi Montpellier France Recruiting

More University Hospital, Montpellier trials in France

Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial Active, not recruiting
Feasibility and Acceptability of Endoscopic Mastectomy in Patients With Breast Cancer Recruiting
Pre-analytical Processing of Human Samples for Microbiota Analysis Quality Starting soon
Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia Active, not recruiting
Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia Recruiting

Other trials for the same condition

Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. Recruiting
Periodontal Microbiota of Patients Candidates for Bariatric Surgery With Body Mass Index Greater Than 30 Recruiting
Determinants of the Long-Term Success of Bariatric Surgery Recruiting
Persistent Organic Pollutants and Mechanical Discharge: Limiting the Impact of Bariatric Surgery Through Personalized Adapted Physical Activity Recruiting
NUTritional Impact of a Hypocaloric Hyperprotein Diet Before Obesity Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02310178 on ClinicalTrials.gov ↗ ← All trials in France